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Objectives: We report the first use of a biorestorative valved conduit (Xeltis pulmonary
valve–XPV) in children. Based on early follow-up data the valve design was modified;
we report on the comparative performance of the two designs at 12 months
post-implantation.
Methods: Twelve children (six male) median age 5 (2 to 12) years and weight 17 (10 to
43) kg, had implantation of the first XPV valve design (XPV-1, group 1; 16mm (n= 5), and
18mm (n = 7). All had had previous surgery. Based on XPV performance at 12 months,
the leaflet design was modified and an additional six children (five male) with complex
malformations, median age 5 (3 to 9) years, and weight 21 (14 to 29) kg underwent
implantation of the new XPV (XPV-2, group 2; 18mm in all). For both subgroups, the 12
month clinical and echocardiographic outcomes were compared.
Results: All patients in both groups have completed 12 months of follow-up. All are
in NYHA functional class I. Seventeen of the 18 conduits have shown no evidence of
progressive stenosis, dilation or aneurysm formation. Residual gradients of >40mm
Hg were observed in three patients in group 1 due to kinking of the conduit (n = 1),
and peripheral stenosis of the branch pulmonary arteries (n = 2). In group 2, one
patient developed rapidly progressive stenosis of the proximal conduit anastomosis,
requiring conduit replacement. Five patients in group 1 developed severe pulmonary
valve regurgitation (PI) due to prolapse of valve leaflet. In contrast, only one patient
in group 2 developed more than mild PI at 12 months, which was not related to
leaflet prolapse.
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Conclusions: The XPV, a biorestorative valved conduit, demonstrated promising early
clinical outcomes in humans with 17 of 18 patients being free of reintervention at 1 year.
Early onset PI seen in the XPV-1 version seems to have been corrected in the XPV-2,
which has led to the approval of an FDA clinical trial.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT02700100
and NCT03022708.
Keywords: pulmonary valved conduit, endogenous tissue restoration, clinical trial, RVOT reconstruction,
biocompatibility
INTRODUCTION
Reconstruction of the right ventricular outflow tract (RVOT)
with a valved conduit is required for a variety of structural
cardiac malformations, and is one of the commonest procedures
in pediatric heart surgery. Currently available valved autografts
and allografts have a limited lifespan, and are constrained by
their inability to grow with the somatic growth of the patient,
necessitating repeated surgery (1). Some of them like homografts
also do not meet the requirements of ready availability and
low antigenicity. Providing a truly restorative alternative for
this patient group has been a long sought-after goal in the
field of cardiovascular tissue engineering, pioneered by the
work of Shinoka et al. (2), who were the first to implant
an in vitro tissue-engineered leaflet replacement in a lamb
model, later continued in the work of Hoerstrup et al. using
in vitro (3). In both approaches, a fast-degrading polymeric
scaffold is seeded in vitro with cells, followed by bioreactor
culture to initiate formation of autologous tissue. More recently,
several research groups have been investigating the addition
of a decellularization step at the end of this process, which
reduces issues observed with leaflet retraction due to presence
of overly active cells and may open doors to non-autologous
(allogeneic) approaches. Particularly worthwhile is the work by
Emmert et al. (4), who showed 1-year functionality in sheep
for a pulmonary valve based on this concept and Reimer
et al. (5), who used a fibrin-based decellularized in vitro tissue
engineered approach to show growth potential in a pulmonary
valve model. To date, these applications have yet to demonstrate
clinical feasibility. Alternative approaches include the use of
decellularized homografts and xenografts as a template for in
situ tissue restoration. The xenograft has been approached with
caution after the porcine Synergraft experience, where a clinical
trial had to be aborted prematurely due to an immune response
to residual porcine cells (6). Decellularized homografts have been
applied with some success in clinic (7), although this approach
does not resolve the issue of shortage of human donor valves. An
alternative approach therefore would be to use an off-the-shelf
fully synthetic implant. Currently used synthetic implants (e.g.,
ePTFE, Dacron) are typically design to be biostable and inert
Abbreviations: XPV, Xeltis pulmonary valve; RVOT, Right ventricular outflow
tract; PI, Pulmonary insufficiency (regurgitation); NYHA, class, New York Heart
Association functional class.
with minimal tissue response. While commonplace for larger
diameter vessels, synthetics face patency limitation for small
diameter (<4mm) vessels. Previous attempts with synthetic
heart valves have faced limited success in clinic, although some
new clinical trials have been initiated recently e.g., using biostable
polyurethane (8) or extra-thin ePTFE (9). The ultimate approach
would combine the benefit of off-the-shelf synthetic materials
with the potential to restore functional natural tissue upon
implantation. This approach is an active topic of academic
research and may vary in whether or not cells and/or bioactive
factors are included to guide tissue outcome (10). Previously
we reported favorable up to 12 months outcomes in sheep for
an off-the-shelf bioabsorbable and restorative pulmonary valved
conduit, which is devoid of any bioactive factors or cells (11). The
current investigation compares the 12 month outcomes of two
small clinical studies with two consecutive designs of the Xeltis
pulmonary valved conduit (XPV).
METHODS
Ethical Approval
Regulatory Authority approvals (or notification, according to
national regulation) were obtained from each country. The
studies were aligned to Good Clinical Practice in compliance
with the “Declaration of Helsinki” (12, 13). Informed consent was
obtained from the parents for all patients prior to the procedure
(ClinicalTrials.gov No: NCT02700100 and NCT03022708).
The Xeltis Pulmonary Valve Conduit
The Xeltis pulmonary valve conduit (XPV) is fully synthetic,
seamless, flexible, highly porous, and bioabsorbable. It makes
use of the RestoreX
TM
polymer platform, which building blocks
are based on supramolecular 2-ureido-4[1H]-pyrimidone (UPy)
(14). The conduit wall consists of poly-caprolactone-based UPy,
and the leaflets are made of poly-carbonate-based UPy, which
provides flexibility for leaflet motion. The implanted graft
material is designed to attract patient’s own cells and proteins,
and trigger a set of events that lead to endogenous tissue
restoration (Figure 1). As the graft resorbs progressively after
implantation, all components of native tissue invade the graft and
the leaflets, and develop and organize into natural tissue (11).
Based on animal histological data it takes up to 12 months for the
leaflets to be functionally replaced with native tissue. As proof
of concept, an initial clinical trial involving valveless conduit
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FIGURE 1 | Artistic impression of intended endogenous tissue restoration process at implant (Top) and microstructural level (Bottom). The porous implant is
functional upon placement and gets permeated with blood components including red and white blood cells and platelets. Subsequently, macrophages are recruited
as part of the host-material response. Macrophages governing tissue remodeling by recruiting other cells including (myo)fibroblasts and endothelials cells and govern
implant absorption by secreting oxygen radicals, eventually resulting in a functionally restored natural implant.
grafts was successfully conducted in a small series of patients
undergoing completion of the Fontan operation by use of an
extracardiac conduit (15). This concept has now been extended
to the addition of a three leaflet valve within the conduit, for
endogenous restoration of the RVOT.
Although XPV conduits of any desired diameter and degree
of leaflet coaptation can be manufactured with the available
technology, the XPVs used in both trials had a diameter of either
16 or 18mm, and an initial conduit length of 8 cm.
Patients
Twelve patients (six male) underwent open heart surgery for
XPV implantation with the initial clinical prototype at one of
three centers worldwide (group 1). Valves were placed in the
normal fashion for a right ventricle to pulmonary artery conduit
and no change in technique was reported by surgeons. Their
median age was 5 years (range 2 to 12), median weight 17 kg
(10 to 43). Individual diagnoses were tetralogy of Fallot (n = 4),
pulmonary atresia with ventricular septal defect (n= 4), common
arterial trunk (n = 3), and transposition of the great arteries
with ventricular septal defect and pulmonary stenosis (n = 1).
All of them had undergone prior open heart surgery to repair
the primary defect; six of them had received a previous valved
conduit, which was replaced by the XPV; the others had had a
transannular patch. Following evaluation of their 12 month post-
surgery outcome (completed in March 2018), modifications in
the valve design were undertaken, and a second cohort of patients
(n = 6, 5 male, group 2) underwent open heart surgery for XPV
implantation between March and October 2018. No change in
technique was reported. These procedures were performed at one
of four North American centers. Their median age was 5 years
(3 to 9 years), and median weight 21 kg (14 to 29). Individual
diagnoses were tetralogy of Fallot (n = 1), pulmonary atresia
with ventricular septal defect (n = 1), transposition of the great
arteries with ventricular septal defect and pulmonary stenosis (n
= 1; and common arterial trunk (n= 1). In two children the XPV
was implanted in the RVOT as part of the Ross procedure (both
patients had previously undergone aortic valve interventions).
Surgery
In group 1, five children had a 16mm diameter conduit
implanted, and seven children received an 18mm diameter
conduit. All patients in group 2 received an 18mm diameter
conduit. In three patients in group 1, the distal pulmonary
arteries were concomitantly enlarged using a pericardial
patch. Transesophageal echocardiography imaging was used
intraoperatively in all subjects.
Modification of the XPV Conduit Design
Prior to Implantation in Group 2
The technology described in this manuscript relies on a gradual
transitioning of functionality from the original implant toward
newly formed patient-own tissue. Early onset of significant
PI at 12 months in group 1 (see Results, below) suggested
that this balance may not have been adequate for all patients,
which prompted technical modifications of the valved conduit.
Retrospective analysis of the first generation XPV conduits
revealed an inhomogeneity in leaflet thickness distribution,
leaflets being thinnest near the commissures. Computational
modeling of the diastolic phase of the cardiac cycle, i.e.,
when pressure over valve is highest, revealed that these thin
areas were correlated with areas of highest leaflet tensile stress
concentration, and bench testing at elevated pressures and
frequencies revealed commissural tear as the most typical
failure mode. The second generation design was therefore
optimized toward increasing thickness in these areas, resulting
in a more homogenous thickness distribution together with a
slight increase in average leaflet thickness. Further increasing
commissural thickness faces limitations due to reduced leaflet
flexibility. Bench testing of the second generation design revealed
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a significant increase in fatigue resistance. In vivo, this is
anticipated to provide more time for the newly formed tissue
to build strength and take over functionality, which may help
improve clinical outcome.
Follow-Up
All children were evaluated clinically, and by serial
echocardiography at hospital discharge, as well as at 6 weeks,
three, six, nine, and 12 months, respectively. Haemodynamic
performance of the conduit was assessed by cross sectional
echocardiography. Stenosis was assessed in the parasternal
short axis view, using the continuous wave Doppler technique
to measure the peak velocity of flow through the conduit. PI
was qualitatively assessed using previously published criteria
combining color flow and pulsed Doppler echocardiography
(16). Regurgitation was classified as none, trivial or trace,
mild, moderate or severe. All echocardiographic studies were
independently analyzed by a core laboratory, which was unaware
of the individual patient’s clinical or demographic data.
Data Collection and Statistical Analysis
All peri- and postoperative data were collected prospectively
according to the detailed clinical study protocol. Data are
described as mean with standard deviation (SD) if continuous,
and as counts and percent if categorical. Minitab 19 (Minitab,
State College, PA, USA) software was used for statistical analysis.
The Anderson—Darling normality test was used to assess
whether the data were normally distributed. In case of normally
distributed data, the t-test was used; in other cases the non-
parametric Mann–Whitney test was applied. All tests were two-
sided. A p < 0.05 was considered statistically significant.
RESULTS
There were no early or late deaths, and no early adverse events.
All children were discharged within seven to 10 days after
surgery. None of the patients in group 1 underwent reoperation
or re-intervention in the first 12 months, while one patient in
group 2 required surgical replacement of the conduit (see below).
Compared to their preoperative functional class (five NYHA class
I, six NYHA class II and one NYHA class III), all 12 patients in
group 1 were in NYHA class I at 12 months. In group 2 5 patients
were in NYHA class I and one in class 2 prior to surgery; all




In nine of the 12 patients in group 1, the peak Doppler gradient
on echocardiography remained below 40mmHg at the 12 month
follow-up (mean gradient of 26.9 ± 20mm Hg at 12 months
for group 1). Of the three children with peak gradients of
>40mm Hg, two patients had undergone concomitant patch
augmentation of the branch pulmonary arteries at the time of
XPV implantation. In both of them the residual gradient could
be demonstrated to be downstream to the distal anastomotic site
of the conduit. One patient showed echocardiographic evidence
of kinking of the conduit at the proximal anastomosis, which
was considered to be a surgical technical issue, and had a peak
Doppler gradient of >40mm Hg at follow-up. In group 2, five of
the six patients had a peak gradient of <40mm Hg at 12 months
(mean gradient of 15.9± 16.4mmHg at 12 months for group 2).
The serial changes in mean Doppler echocardiographic gradient
up to 12 months of follow-up are shown in Figure 2.
One child in group 2, with a diagnosis of tuberous sclerosis
and multiple cardiac rhabdomyomas, had undergone balloon
valvuloplasty of the aortic valve at 3 months and 7 months of
age. At 10 months, the child underwent surgical excision of two
rhabdomyomas at the base of the aortic leaflets, with concomitant
left ventricular myectomy and aortic valve repair. At 4 years, a
Ross operation was performed (replacement of the aortic root
with use of the pulmonary autograft, and implantation of an
18mm XPV conduit in the pulmonary position) for recurrent
left ventricular outflow tract obstruction secondary to scarring
of the area. At several time points the child had been noted
to have a hyperinflammatory reaction to various interventions,
and had been on immunosuppressive therapy, followed by
oral ibuprofen prior to XPV implantation. Post XPV implant
follow-up was clinically uneventful. At 6 months, a moderate
gradient was seen on echocardiography (peak gradient 44mm
Hg; mean 20mm Hg) at the site of the proximal anastomosis.
These findings were reconfirmed at 9 months (moderate RVOT
obstruction and mild PI). Nine days after the 9 month follow-
up the patient presented with acute abdominal discomfort.
Echocardiographic examination at that admission demonstrated
severe conduit stenosis, and right ventricular dysfunction. The
XPV conduit was explanted and a Contegra graft implanted. At
surgery there was severe stenosis at the proximal and distal suture
lines. Histological examination of the explanted XPV conduit
showed organized fibrin on the luminal surface, with minimal
inflammation and no neovascularization. There was intimal
scarring at the proximal and distal anastomotic sites, confirming
past findings for this patient. The valve leaflets were intact, with
evidence of mild commissural fusion (Figure 3). Small thrombi
were seen in two of the three valve sinuses. Despite the dramatic
clinical course with deterioration within 9 days following an
uneventful clinical and echocardiographic examination, these
findings were attributed to a hyperinflammatory response which
might be peculiar to tuberous sclerosis (17). The current
Contegra conduit has also experienced premature narrowing
prompting the use of immune modulating medication. This
type of patient will require careful consideration prior to XPV
implants in the future.
Diameter
There was a non-significant change in conduit diameter during
follow-up in both groups. None of the conduits demonstrated
aneurysm formation, or stenosis within the conduit outside of
the suture lines, over time. Only one patient in group 2 (see
description above) developed suture line stenosis at follow-
up, possibly attributable to his co-morbid condition (tuberous
sclerosis). Serial changes in RVOT diameter are shown in
Figure 4.
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TABLE 1 | Summary of patient outcomes.
Patient ID Mean gradient [mmHg] PI severity RVOT diameter [mm] RV diastolic area [cm2] NYHA class
7D 6M 12M 7D 6M 12M 7D 6M 12M 7D 6M 12M Baseline 12M
GROUP 1
1 14 11 10 Mild Trace Mod 16 15 14 8.4 9.0 10.2 III I
2 12 15 25 Trace Mod Mod 15 18 17 18.1 19.1 23.8 II I
3 10 7 7 Mild Mild Mild 15 13 15 11.4 10.6 14.4 I I
4 16 14 20 Trace Mild Sev 15 14 14 9.1 9.7 12.8 II I
5 10 9 10 None Mild Mod 17 14 14 15.6 13.2 17.6 II I
6 26 21 19 Trace Mod Mod 15 18 19 17.8 22.9 * II I
7 29 27 40 Mild Mod Mod 17 19 22 20.3 24.1 24.7 II I
8 11 20 29 Trace Mild Mod 17 15 15 17.2 16.9 20.3 I I
9 13 30 23 Mild Sev Sev 17 14 15 11.5 11.1 11.9 I I
10 23 20 42 Mild Mod Sev 17 14 16 11.6 14.0 14.0 I I
11 14 18 18 Mild Sev Sev 13 16 17 * * 16.6 I I
12 39 64 80 Mild Sev Sev * * 22 25.9 35.4 32.9 II I
GROUP 2
13 20 19 16 Mild Mild Trace 16 16 16 12.3 13.1 13.8 II *
14 10 15 20 None None Mod 19 20 19 19.4 19.9 23.1 I I
15 8 14 6 Mild Trace Mild 18 18 17 12.2 * 8.0 I I
16 10 9 10 Trace Trace Mild 16 17 15 10.5 14.8 11.7 I I
17 31 22 27 Mild Mild Mild 15 18 18 * 18.4 18.0 I I
18 10 20 * Mild Mild * 18 * * * * * I *
7D, 7 days post-surgery; 6M, 6months; 12M, 12months; PI, Pulmonary Insufficiency, classified as None, Trace, Mild, Moderate (Mod) or Severe (Sev). NYHA, New York Heart Association
(NYHA) classification of limitation during physical activity: I -No limitation II -Slight limitation III -Marked limitation IV -Unable without discomfort. * Data not available.
FIGURE 2 | Mean Doppler gradients (mm Hg), for both groups, from hospital
discharge up to 12 months. D7, 7 days post-surgery; 6M, 6 months; 12M, 12
months.
Pulmonary Regurgitation
At hospital discharge, PI in group 1 was graded as “none to
mild” in all patients. At 12 months, five patients had developed
severe PI, and six hadmoderate regurgitation. Anatomical factors
associated with the development of significant PI were analyzed.
Two patients had significant residual gradients at the level of
the branch pulmonary arteries, which could have contributed to
the PI. Kinking of the conduit could have contributed to PI in
FIGURE 3 | Downstream (left hand panel, looking from the side of the
pulmonary trunk, and upstream (looking from the RV side, right hand panel) of
the explanted conduit. The leaflets are well-preserved, with mild commissural
fusion at the base. The lumen of the conduit is also smooth, without evidence
of excessive tissue proliferation or potential obstruction.
one patient. The commonest mechanism of PI was prolapse (or
flailing) of one of the three leaflets of the valve. This could be
definitively identified in three patients, and was thought to be
the potential mechanism in two others. Prolapse of a leaflet was
first observed at the 6 month follow-up echocardiogram in three
patients, and at the 12 month study in two others. In group 2, PI
grade was “none or mild” in all six patients at hospital discharge.
At 12 months, PI was mild in 4 patients, and moderate in
one; in particular no patient demonstrated prolapse, or potential
prolapse, of any of the valve leaflets. One patient required re-
operation at 9 months (see above); the last echocardiogram prior
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FIGURE 4 | Serial changes in minimum conduit diameters (mm) at follow-up,
for both groups. Time intervals are as for Figure 1.
to XPV replacement graded PI as “mild” in this child. Figure 5 is
a frequency histogram of the grade of PI at discharge, 6 and 12
months follow-up.
Right Ventricular Size and Area
Right ventricular end diastolic diameters (RVEDD) were
measured serially at three separate sites; the basal segment at the
level of the tricuspid valve annulus (basal), at mid-cavity level,
and at the level of the RVOT, below the level of the conduit.
The obtained diameters were used to calculate RV diastolic area
(Figure 6). The only statistical difference between discharge and
12 months was found for the diastolic area of 16mm group 1
valves (p = 0.02). No statistical differences were found for any
RV parameters between groups (p > 0.05 in all cases). Also, on
comparing group 1 patients with severe PI (n = 5) to those with
less than severe PI (n = 7), none of the measurements showed
any significant difference between the two subsets.
DISCUSSION
A wide variety of conduits are commercially available, but the
perfect conduit unfortunately does not still exist. To date, the
gold standard for RVOT reconstruction has been the allograft,
harvested from cadavers. Valved pulmonary allografts were
originally introduced by Ross et al. (18). They have been shown
to be durable, particularly in adults. In the pediatric population,
structural deterioration of the conduit leads to inevitable
replacement (19–21). Particularly in young patients, conduit
dysfunction, with resulting stenosis and valvar insufficiency,
may be related to geometric distortion during the implant
procedure. Wells et al. demonstrated that somatic outgrowth
was not the major cause of allograft conduit failures in young
patients. Failure was primarily due to conduit stenosis, with
an additional 30% failure rate due to technical issues during
surgery (22). Early allograft (or xenograft) conduit deterioration
may be related to recipient immunological reactions, as has
been suggested in several studies. Rajani et al. demonstrated
histological evidence for rejection in allograft valves explanted
from the right ventricular outflow tract in children. All valves
implanted in infants had failed at>12 months following implant.
All of them showed multiple foci of inflammation consisting
of T lymphocytes (18). Similar findings were reported by Vogt
and colleagues, from allograft material explanted from the
right ventricular outflow tract (23). The limited availability of
homografts has meant that allografts are increasingly used in
clinical practice, such as the Contegra, a bovine jugular vein
derived conduit. However, it is associated with the development
of stenosis at the distal anastomosis, which may not be due
to surgical technical issues. Histological study of the explanted
conduits showed fibrointimal proliferation and peel formation
at the distal anastomotic site, which obstructed the lumen (20).
Meyns et al. demonstrated similar histologic findings in failed
Contegra conduits, and suggested that the risk of development
of distal stenosis did not change over time (24). Freedom from
severe stenosis (defined as an echocardiographic peak gradient of
>50mm Hg) at the distal anastomosis was <50% at 24 months
following conduit implantation. The authors hypothesized that
chronic movement of the graft wall at the level of the anastomosis
(a function related to the high degree of pliability of the Contegra
graft) could cause repetitive trauma and be the ongoing trigger
for fibrointimal peel formation. The FDA reported composite
conduit failure rates at 1 year of 25% and 22% for the Contegra
graft’s FDAHDE submission (n= 237) and post-marketing study
(n = 374), respectively, suggesting that alternatives are clearly
required (22).
The XPV conduit has been designed to enable endogenous
tissue restoration. No cell seeding, growth factors or other
active ingredients were incorporated to guide the restoration
process Nonetheless, animal studies with the XPV conduit
showed complete coverage of the conduit wall with neointima
was observed at 2 months after implantation. The leaflets
themselves were functionally replaced with a well-vascularized
collagen-rich connective tissue at between six and 12 months.
Part of the promising performance of the XPV conduit
may be attributed to the supramolecular RestoreX
TM
polymer
platform. Its supramolecular UPy motif provides excellent
mechanical strength at relatively low molecular weights, which
facilitates the electrospinning process. In addition, the UPy
motif provides a polymer platform, allowing tailored chemistry,
such as a more slowly absorbing and flexible PC-UPy for
the leaflets vs. a more stiff but faster absorbing PCL-UPy for
the conduits. Finally, the XPV conduit appears to provide a
favorable microenvironment for endogenous tissue restoration.
Recent work using a subcutaneous rat model demonstrates
that RestoreX
TM
trigger a dominant M2 macrophage response,
which is a unique observation for synthetic materials, and
is associated with a pro-remodeling tissue response. The
mechanisms behind this predominant M2 response are subject of
active investigation.
The handling properties of the XPV conduit are comparable
to those of other synthetic conduits such as PTFE or Dacron,
and conduits can be cut and refashioned during surgery.
One patient in group 1 developed conduit stenosis due to a
technical issue, with kinking of the conduit at implantation.
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FIGURE 5 | Frequency histogram of PI for both groups. Time intervals are as for Figure 1.
FIGURE 6 | Calculated diastolic area for both groups. Time intervals are as for
Figure 1.
This most likely also led to early onset of PI in this patient.
One child in group 2, as described above, required early
conduit replacement. The dramatic clinical presentation, with
acute conduit stenosis and right ventricular failure 9 days after
a seemingly normal routine follow-up 9 months post-XPV
implantation, defies clear explanation. Tuberous sclerosis can be
associated with overexpression of the complement pathways, and
a hyperimmune reaction (16). The patient’s current Contegra
conduit has experienced the same process of early recurrence
of stenosis. Importantly, apart from intimal scarring at the
anastomotic lines, the lumen and leaflets of the explanted XPV-2
conduit did not exhibit any signs of degeneration.
An important finding in group 1 was the occurrence of
severe PI in five of the 12 implanted conduits at the 12
months. The commonest identifiable mechanism for PI was
prolapse of one of the valve cusps. A possible mechanism for
leaflet prolapse and the development of significant PI could
be early loss of mechanical integrity of the bioabsorbable
foundation, and insufficient replacement by native material
within this time frame, resulting in the leaflets being inadequately
supported resulting in leaflet prolapse and loss of coaptation.
This led to modification of leaflet design, as described, with
improved thickness homogeneity of the leaflets. Bench testing
demonstrated that the improved design had a significantly longer
fatigue life, which is anticipated to provide more time for
endogenous tissue to restore and take over functionality. First
signs of improved clinical function are promising, showing a
marked reduction in degree of severity of PI in group 2 at
12 months post-implant. It should be noted that this ability
to learn and adapt based on clinical findings is an important
and unique asset of the RestoreX
TM
platform, which may prove
essential when expanding to larger patient groups and additional
indications. For example, promising acute preclinical results
using RestoreX for aortic valve restoration were previously
reported (25).
Potential Limitations
A relatively large number of centers have been involved
in the study, with the possible result that surgical and
technical issues were not addressed in a standardized
way. The duration of follow-up is short, and hence graft
growth to match somatic growth of the patient has not
been demonstrated.
CONCLUSIONS
The XPV conduit can be fashioned to any desired size, thickness,
and degrees of leaflet coaptation, and made to specification.
Degeneration of the conduit resulting in aneurysmal dilation
has not been observed, and only one of 18 patients developed
conduit stenosis, albeit under dramatic circumstances and
for reasons that are unclear, but possibly related to an
underlying inflammatory disorder. Improving leaflet strength
has demonstrably proven that PI could be reduced in the
short term as demonstrated by the XPV-2, demonstrating the
potential of the RestoreX
TM
technology to adapt based on
clinical learnings. Although patient numbers are small, and
follow-up times are short, these results offer promising signs
of the potential of this technology to change the treatment
paradigm for children requiring RVOT reconstruction. The
present outcome has allowed for an FDA clinical trial to be
approved so that longer term follow-up of the current conduit
design can be assessed.
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